Company Description

MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.

Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

MAIA Biotechnology, Inc.

Country	United States
Founded	2018
IPO Date	Jul 28, 2022
Industry	Biotechnology
Sector	Healthcare
Employees	13
CEO	Vlad Vitoc

Contact Details

Address: 444 West Lake Street, Suite 1700 Chicago, Illinois 60606 United States
Phone	312 416 8592
Website	maiabiotech.com

Stock Details

Ticker Symbol	MAIA
Exchange	NYSEAMERICAN
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$5.00
CIK Code	0001878313
CUSIP Number	552641102
ISIN Number	US5526411021
SIC Code	2834

Key Executives

Name	Position
Dr. Vlad Vitoc M.B.A., M.D.	Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors
Jeffrey C. Himmelreich	Head of Finance
Dr. Sergei M. Gryaznov Ph.D.	Chief Scientific Officer
Linda Moreira	Company Secretary

Latest SEC Filings

Date	Type	Title
Nov 12, 2024	10-Q	Quarterly Report
Nov 12, 2024	D	Notice of Exempt Offering of Securities
Nov 8, 2024	8-K	Current Report
Nov 5, 2024	8-K	Current Report
Oct 29, 2024	8-K	Current Report
Oct 25, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Oct 25, 2024	SC 13D	General statement of acquisition of beneficial ownership
Oct 25, 2024	SC 13D	General statement of acquisition of beneficial ownership
Sep 10, 2024	8-K	Current Report
Aug 9, 2024	10-Q	Quarterly Report

View All SEC Filings